Skip to main content

Table 4 Significant therapeutic drugs predicted by Cmap

From: Prognostic value and immune relevancy of a combined autophagy-, apoptosis- and necrosis-related gene signature in glioblastoma

Drug Name

Mechanism of Action

Target

Score

Tipifarnib

Farnesyltransferase inhibitor

FNTA, FNTB

-96.1

Tofacitinib

JAK inhibitor

JAK3, JAK1, JAK2, CYP2C19, TYK2

-95.81

GSK-1070916

Aurora kinase inhibitor

AURKB, AURKC, AURKA, CYP2D6, CYP3A4

-94.93

Mestranol

Estrogen receptor agonist

ESR1

-94.48

Ruxolitinib

JAK inhibitor

JAK1, JAK2, TYK2, JAK3

-93.19

XMD-1150

Leucine rich repeat kinase inhibitor

LRRK2

-92.64

TPCA-1

IKK inhibitor

IKBKB

-91.9

PPT

Estrogen receptor agonist

ESR1

-91.84

7,4'-dihydroxyflavone

Opioid receptor antagonist

CYP19A1

-91.29

Phorbol-12-myristate-13-acetate

PKC activator

CD4, KCNT2, PRKCA, TRPV4

90.49

BX-795

IKK inhibitor

PDPK1, CDK2, CHEK1, GSK3B, IKBKE, KDR, PDK1, TBK1

92.53

Arecaidine

Acetylcholine receptor agonist

CHRM1, CHRM2, CHRM3, CHRM4

92.67

NSC-94258

Antineoplastic

AKR1B1, CYP19A1, HSD17B1

93.08

Scoulerine

Adrenergic receptor antagonist, GABA receptor antagonist, Serotonin receptor antagonist

ADRA1D, ADRA2A, GABRA1

95.29

Prostratin

PKC activator

PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCH, PRKCQ

95.81

Ingenol

PKC activator

PRKCD, PRKCE

96.05